CompletedPhase 3NCT02562066
Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes
Studying Congenital myasthenic syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Catalyst Pharmaceuticals, Inc.
- Principal Investigator
- Thomas Crawford, M.D.Johns Hopkins Pediatric Neurology
- Intervention
- amifampridine phosphate(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 2-70 years · All sexes
- Timeline
- 2016 – 2019
Study locations (4)
- UCLA Department of Neurology, Los Angeles, California, United States
- Johns Hopkins Pediatric Neurology, Baltimore, Maryland, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Ohio State University, Columbus, Ohio, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02562066 on ClinicalTrials.govOther trials for Congenital myasthenic syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06630650A Prospective Natural History and Outcome Measure Validation Study of Congenital Myasthenic SyndromesNational Institute of Neurological Disorders and Stroke (NINDS)
- RECRUITINGPHASE1NCT07226726Patients With Congenital Myasthenic Syndrome Will be Treated With Mesenchymal Stem Cell Exosome SolutionThe Foundation for Orthopaedics and Regenerative Medicine
- RECRUITINGPHASE1NCT06436742A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)argenx
- RECRUITINGNCT06078553A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4argenx